With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of approved agents with diverse mechanisms of action to treat the disease. In recent years, the dynamics of the psoriasis market have started to change; there has been a shift from the use of established TNF-α inhibitors as earlier-line agents to the earlier use of other biologics like the IL-12/23 inhibitor Stelara, IL-17 inhibitors such as Cosentyx and Taltz, and IL-23 inhibitors such as Tremfya and Skyrizi. Nonetheless, the early- and late-phase pipeline for moderate to severe psoriasis has several promising agents because drug developers realize that, despite multiple current treatments, novel agents are needed that can differentiate themselves on the attributes of efficacy, safety, convenient delivery, and ability to treat a broad patient population.
QUESTIONS ANSWERED
- How do dermatologists rate current therapies’ performance on key treatment drivers and goals for moderate to severe psoriasis?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities in moderate to severe psoriasis?
- What are the prevailing areas of unmet need and opportunity in the treatment of moderate to severe psoriasis?
- What trade-offs across key clinical / non-clinical attributes and price are acceptable to dermatologists for a hypothetical new drug for moderate to severe psoriasis?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 32 European dermatologists fielded in February 2022
Key companies: AbbVie, Novartis, Janssen, Eli Lilly, Amgen
Key drugs: Cosentyx, Humira, Otezla, Skyrizi, Stelara, Taltz, Tremfya
- Psoriasis - Unmet Need - Detailed, Expanded Analysis: Moderate To Severe Psoriasis
- Executive summary
- Unmet Need - moderate to severe psoriasis - executive summary - May 2022
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products for moderate to severe psoriasis and rationale for drug selection
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed dermatologists' prescribing decisions in moderate to severe psoriasis
- Importance of efficacy attributes to prescribing decisions in moderate to severe psoriasis: United States
- Importance of efficacy attributes to prescribing decisions in moderate to severe psoriasis: Europe
- Importance of safety and tolerability attributes to prescribing decisions in moderate to severe psoriasis: United States
- Importance of safety and tolerability attributes to prescribing decisions in moderate to severe psoriasis: Europe
- Importance of convenience of administration attributes to prescribing decisions in moderate to severe psoriasis: United States
- Importance of convenience of administration attributes to prescribing decisions in moderate to severe psoriasis: Europe
- Importance of nonclinical factors to prescribing decisions in moderate to severe psoriasis: United States
- Importance of nonclinical factors to prescribing decisions in moderate to severe psoriasis: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in moderate to severe psoriasis: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in moderate to severe psoriasis: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for moderate to severe psoriasis: United States
- Overall performance of key therapies for moderate to severe psoriasis: Europe
- Mean overall performance of key therapies for moderate to severe psoriasis: United States and Europe
- Relative performance of key therapies for moderate to severe psoriasis across select efficacy attributes: United States
- Relative performance of key therapies for moderate to severe psoriasis across select efficacy attributes: Europe
- Relative performance of key therapies for moderate to severe psoriasis across select safety and tolerability attributes: United States
- Relative performance of key therapies for moderate to severe psoriasis across select safety and tolerability attributes: Europe
- Relative performance of key therapies for moderate to severe psoriasis across select convenience of administration attributes: United States
- Relative performance of key therapies for moderate to severe psoriasis across select convenience of administration attributes: Europe
- Relative performance of key therapies for moderate to severe psoriasis across select nonclinical attributes: United States
- Relative performance of key therapies for moderate to severe psoriasis across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in moderate to severe psoriasis
- Surveyed dermatologistsu2019 satisfaction with the performance of key therapies for moderate to severe psoriasis on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed dermatologistsu2019 satisfaction with the performance of key therapies for moderate to severe psoriasis on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed dermatologists' ascribed level of unmet need across key efficacy attributes in moderate to severe psoriasis: United States
- Surveyed dermatologists' ascribed level of unmet need across key efficacy attributes in moderate to severe psoriasis: Europe
- Surveyed dermatologists' ascribed level of unmet need across key safety and tolerability attributes in moderate to severe psoriasis: United States
- Surveyed dermatologists' ascribed level of unmet need across key safety and tolerability attributes in moderate to severe psoriasis: Europe
- Surveyed dermatologists' ascribed level of unmet need across key convenience of administration attributes in moderate to severe psoriasis: United States
- Surveyed dermatologists' ascribed level of unmet need across key convenience of administration attributes in moderate to severe psoriasis: Europe
- Surveyed dermatologists' ascribed level of unmet need across key nonclinical factors in moderate to severe psoriasis: United States
- Surveyed dermatologists' ascribed level of unmet need across key nonclinical factors in moderate to severe psoriasis: Europe
- Key findings: unmet need in moderate to severe psoriasis and related indications
- Surveyed dermatologists' ascribed level of unmet need in moderate to severe psoriasis and related indications: United States
- Surveyed dermatologists' ascribed level of unmet need in moderate to severe psoriasis and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the moderate to severe psoriasis market and emerging therapy insights
- Opportunity: a novel agent offering improved sustained efficacy in moderate to severe psoriasis
- Opportunity: a novel agent offering efficacy in a broad patient population
- Opportunity: a novel agent that improves patients' quality of life
- Target product profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Attribute importance and part-worth utilities
- Moderate to severe psoriasis target product profile: attribute importance
- PASI 90 Response at week 16 (% of patients)
- Maintenance of PASI 75 response at week 60 (% of patients)
- Median time to PASI 90 response rate (weeks)
- sPGA score of clear or almost clear skin (0 or 1) at week 16 (% of patients)
- Rate of serious adverse events
- Route and frequency of administration
- Price / day
- Conjoint analysis-based simulation of a market scenario
- Moderate to severe psoriasis market simulation: share of preference of target product profiles included in the market scenario
- Moderate to severe psoriasis market simulation: likelihood to prescribe target product profiles included in the market scenario
- Moderate to severe psoriasis market simulation: target product profiles included in the market scenario
- Appendix
- Experts interviewed
- Bibliography